No products in the cart.
LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM) that is unique in the world of SARMs as it is the only SARM to have been researched in clinical trials for use by healthy, human men. LGD-4033 research studies are trying to verify whether or not LGD-4033 would be safe for use by men, particularly athletes looking to increase the size of their muscle and gain improved athletic performance abilities. The world of professional sports is no stranger to the use of SARMs, including LGD-4033. Joakim Noah from the Knicks basketball team was once suspended for twenty games due to having LGD-4033 in his system, as it is an unapproved health supplement under the rules of the NBA.
What Do SARMs Do?
Selective androgen receptor modulators act on the androgen receptor gene. When activated, it will bind to androgenic hormones like testosterone, DHEA, and DHT. The androgen receptor has a few responsibilities in the bodies of both males and females. In males, androgens are responsible for the testosterone hormone that promotes masculinity, including muscle growth and a healthy sex drive. In females, the androgen receptor regulates the growth of hair and sex drive, and can be converted to estrogen in the ovaries.
LGD-4033 is a SARM with the possibility for treating hormone related concerns such as loss of muscle and aging-related diseases. In the past, these diseases and muscle wasting conditions would be treated with testosterone, which will improve muscle wasting, some cancer conditions, and aging-related diseases – but it also affects brain activity and hormones with unwanted side effects. SARMs like LGD-4033 may be able to deliver the anabolic benefits of testosterone without the hormonal side effects since SARMS are selective in their binding nature whereas testosterone is not.
Potential Benefits of LGD-4033
Several studies involving LGD-4033 report potential benefits of the SARM may include an increase in lean muscle mass and improvement in the body’s bone density. Clinical studies report the results can be achieved with low doses and minimal use, and upon completing the dosing period, hormone and lipid levels return to normal. More scientific research would be needed to understand why muscle mass is increased favorably while using LGD-4033 but fat mass levels do not change.
LGD-4033 Research and Clinical Studies
A 21-day study was conducted in 2013 with 76 willing, healthy male subjects ranging in age from 21 to 50 years old. LGD-4033 was studied by researchers hoping to analyze whether the SARM would be tolerated safely by the body and whether or not it would target the processes of human muscle.
For a period of 21 days, men received a dose of LGD-4033. For five weeks beyond the dosing period, the men were studied and their hormones, mass, fat, and strength were monitored. It was found that participants experienced an increase of lean muscle mass but no change in prostate antigen. Upon conclusion of the human-based study, researchers recommended longer studies of LGD-4033 in order to more fully understand health benefits and potential outcomes of the SARM.